SmartNuclide Biopharma

Executive Summary

SmartNuclide Biopharma is a clinical-stage Chinese biotech pioneering next-generation radiopharmaceuticals for oncology, with a focus on targeted alpha-particle therapy (TAT) and radioligand therapy (RLT). Founded in 2020 and based in Shanghai, the company aims to deliver precise radiation to solid tumors while sparing healthy tissue, addressing high unmet medical needs. Its core platform integrates novel targeting ligands with potent radioisotopes to enable highly selective cancer cell killing. As a private company with 50–200 employees, SmartNuclide has advanced into Phase 1 clinical development, leveraging proprietary technology to differentiate itself in the rapidly growing radiopharma space. The company's lead program is currently in Phase 1 dose-escalation studies for multiple solid tumor indications, with initial safety and efficacy data expected soon. Given the rising global interest in radiopharmaceuticals and targeted therapies, successful proof-of-concept could unlock significant value through partnerships or further clinical expansion. Key upcoming milestones include Phase 1 data readouts, potential initiation of Phase 2 trials, and regulatory submissions in China or the US. SmartNuclide's early-stage focus and innovative platform position it as a high-upside opportunity in the oncology radiopharma landscape.

Upcoming Catalysts (preview)

• Q1 2027Phase 1 dose-escalation data readout for lead TAT candidate45% success
• Q4 2026IND filing for second-generation RLT candidate70% success
• H1 2027Strategic partnership or licensing deal for Greater China rights40% success